Alzheimer's Rollercoaster: Azeliragon Misses Endpoints, But Responding Subgroup Identified
US biotech vTv Therapeutics has again reported disappointing top-line Phase III clinical study results for its potential Alzheimer's disease therapy, azeliragon, but believes it has identified a possible path to continued development.
You may also be interested in...
Just weeks after Johnson & Johnson halted development of its BACE inhibitor for Alzheimer's and a few months after Merck & Co failed at Phase III, Lilly and AstraZeneca end trials of lanabecestat.
Multiple competitors have ended development of BACE inhibitors for the treatment of Alzheimer's disease, but Eisai neurology executive Lynn Kramer tells Scrip that the company still sees a path forward for certain amyloid-targeting drugs.
Boehringer's investigational drug, BI 409306, is the second big pharma PDE9 inhibitor to fail in Alzheimer's clinical trials; Eisai is still standing with a Phase I compound but the odds are not in its favor.